Literature DB >> 9648964

Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma.

H Bisgaard1, B Klug, B S Sumby, P K Burnell.   

Abstract

The study aimed to investigate dose consistency and particle distribution from the dry powder inhalers Diskus and Turbuhaler. Full profiles of inhalation pressure versus time were recorded in 18 4 yr old and 18 8 yr old asthmatic children through Diskus and Turbuhaler inhalers. These data were used in an inhalation profile simulator to assess drug delivery from both a Diskus inhaler and a Turbuhaler inhaler, and in particular to assess the proportion of drug emitted in the coarse (>4.7 microm) and fine (<4.7 microm) particle size range from each type of inhaler. The inhalation profile more accurately represents the changes in flow rate over time through the device than the constant flow rate usually applied with an impactor alone. The aerosol cloud was released before the peak inspiratory effort had been achieved and accordingly the early part and not the peak of the inspiratory performance is a determinant of the quality of the aerosol. The mean (SD) amount of drug in large particles (>4.7 microm), fine particles (<4.7 microm) and very fine particles (<2.1 microm) in percentage of label claim from the Fluticasone Diskus was 72 (5), 15 (2) and 2 (1) from the 4 yr old children and 71 (3), 18 (2) and 2 (1) from the 8 yr old children, respectively. Similar particle fractions from the Budesonide Turbuhaler were 35 (9), 21 (10) and 7 (5) from 4 yr old children and 30 (7), 32 (9) and 12 (6) from 8 yr old children. In conclusion, the Diskus inhaler provides an improved dose consistency through the varying age groups and inspiratory flow performances when compared to the Turbuhaler in terms of the proportion of the dose emitted at each particle size. This improvement is at the expense of a low fine particle mass and a high proportion of coarse particles from the Diskus as compared with the Turbuhaler.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9648964     DOI: 10.1183/09031936.98.11051111

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  15 in total

1.  Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects.

Authors:  T W Harrison; A E Tattersfield
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

2.  Inhalation devices.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 3.  Once-daily inhaled corticosteroids in children with asthma: dry powder inhalers.

Authors:  C Möller
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 4.  Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.

Authors:  Sohini Ghosh; Jill A Ohar; M Bradley Drummond
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-09-21       Impact factor: 2.849

5.  Salbutamol pMDI gives less protection to methacholine induced airway obstruction than salbutamol via spacer or DPI.

Authors:  Mariëlle E A C Broeders; Johan Molema; Wim C J Hop; Hans Th M Folgering
Journal:  Eur J Clin Pharmacol       Date:  2004-12-30       Impact factor: 2.953

6.  Reduced Peak Inspiratory Effort through the Diskus((R)) and the Turbuhaler((R)) due to Mishandling is Common in Clinical Practice.

Authors:  Andrea S Melani; Letizia S Bracci; Marcello Rossi
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

7.  Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®).

Authors:  L Pekka Malmberg; Mark L Everard; Jussi Haikarainen; Satu Lähelmä
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-06-30       Impact factor: 2.849

Review 8.  Use of inhaler devices in pediatric asthma.

Authors:  Fernando Maria De Benedictis; David Selvaggio
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.

Authors:  Chris Dalby; Tomasz Polanowski; Thomas Larsson; Lars Borgström; Staffan Edsbäcker; Tim W Harrison
Journal:  Respir Res       Date:  2009-10-31

Review 10.  The Diskus: a review of its position among dry powder inhaler devices.

Authors:  H Chrystyn
Journal:  Int J Clin Pract       Date:  2007-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.